Human Embryonic Stem Cell-based Xcel Cell Therapy Product Prototypes

Provide the only available human cell sources in large commercial scales with adequate cellular pharmacologic capacity to regenerate the neurons and contractile heart muscles, vital for neurological and heart repair for a wide range of neurological and cardiovascular diseases in the clinical setting, and for creating human CNS- and heart-related tissue or organ products, including Xcel-hCardP, Xcel-hCM, Xcel-hNuP, Xcel-hNu. Our hESC therapy products represent the next generation of human cell therapy products, offering purity, large-scale production, high quality, safety, and effectiveness for commercial and therapeutic uses over all other existing human cell sources or products. Our hESC therapy products will not only significantly increase the success rate in clinical trials and reduce the costs of registration pipeline as they reach cGMP-compliance and subsequent clinical phases, but also qualify for FDA RMAT Designation to accelerate regulatory approval and patient access to new therapies.


Pluripotent human embryonic stem cell-derived, clinical-grade high purity human neuronal progenitor cells/neurons for neuron regeneration or replacement therapies, targeting Parkinson’s disease (PD), Alzheimer disease (AD), spinal cord injury (SCI), traumatic brain injury (TBI), amyotrophic lateral sclerosis (ALS), spinal muscular atrophy (AMS), and stroke.


Pluripotent human embryonic stem cell-derived, clinical-grade high purity human heart precursor cells/cardiomyocytes for contractile heart muscle regeneration or replacement therapies, targeting heart disease and failure.


Parsons XH. PluriXcel: Emerging Technologies of Regenerative Medicine. LAP Lambert Academic Publishing, 2016; Chapter 1-23:1-526. Book ISBN-13: 978-3-659-95970-7; ISBN-10: 3659959707; EAN: 9783659959707.

Parsons XH. Direct conversion of pluripotent human embryonic stem cells (human ES cells) under defined culture conditions into human neuronal or cardiomyocytes cell therapy derivatives. Methods Mol. Biol. 2016;1307:299-318. Chapter on Human Embryonic Stem Cells: Methods and Protocols, 2nd Edition. Springer’s Protocols. doi: 10.1007/7651_2014_69. PMID: 24500898.

Parsons XH. Directing pluripotent human embryonic stem cells towards lineage-specific cell therapy derivatives for regenerative medicine. Chapter covering human embryonic stem cells, Gene and Cell Therapy: Therapeutic Mechanisms and Strategies, 4th Edition, edited by Nancy Smyth Templeton, CRC Press, 2015; Chapter 31:795-818, Taylor and Francis, Print ISBN: 978-1-4665-7199-0, eBook ISBN: 978-1-4665-7200-3.

Parsons XH. Constraining the pluripotent fate of human embryonic stem cells for tissue engineering and cell therapy – the turning point of cell-based regenerative medicine. British Biotech. J. 2013;3(4):424-457. doi: 10.9734/BBJ/2013/4309#sthash.6D8Rulbv.dpuf. PMID: 24926434. PMCID: 4051304.

Parsons XH. Embedding the future of regenerative medicine into the open epigenomic landscape of pluripotent human embryonic stem cells. Ann. Rev. Res. Biol. 2013;3(4):323-349. PMID: 25309947. PMCID: 4190676.

Parsons XH. Human stem cell derivatives retain more open epigenomic landscape when derived from pluripotent cells than from tissues. J. Regen. Med. 2013;1:2. doi: 10.4172/2325-9620.1000103. PMID: 23936871. PMCID: 3736349.

Parsons XH, Parsons JF, Moore DA. Genome-scale mapping of microRNA signatures in human embryonic stem cell neurogenesis. Mol. Med. Ther. 2013;1:2. doi: 10.4172/2324-8769.1000105. PMID: 23543894. PMCID: 3609664.

Parsons XH. An engraftable human embryonic stem cell neuronal lineage-specific derivative retains embryonic chromatin plasticity for scale-up CNS regeneration. J. Reg. Med. & Tissue Eng. 2012;1:3. doi: 10.7243/2050-1218-1-3. PMID: 23542901. PMCID: 3609668.

Parsons XH. MicroRNA profiling reveals distinct mechanisms governing cardiac and neural lineage-specification of pluripotent human embryonic stem cells. J. Stem Cell Res. Ther. 2012;2:124. doi: 10.4172/2157-7633.1000124. PMID: 23355957. PMCID: 3554249.

Parsons JF, et al. Defining conditions for sustaining epiblast pluripotence enables direct induction of clinically-suitable human myocardial grafts from biologics-free human embryonic stem cells. J. Clinic. Exp. Cardiology 2012;S9-001. doi: 10.4172/2155-9880.S9-001. (Special Issue on Heart Transplantation). PMID: 22905333. PMCID: 3419496.